Author

Vitalina Dzutseva

Institutions: Novosibirsk State University, AstraZeneca (United States)

Observed institutions: Novosibirsk State University, AstraZeneca (United States)

ORCID: 0000-0002-5630-755X

Observed ORCID: 0000-0002-5630-755X

OpenAlex ID: A5001502849

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

2021 · Scott A Halperin, Lingyun Ye, et al. · The Lancet · 234

Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein

2024 · Saveliy A. Sheetikov, Alexandra A. Khmelevskaya, et al. · Frontiers in Immunology · 8

Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia

2023 · Dmitry Lioznov, Irina Amosova, et al. · PLoS ONE · 8

P-1960. Safety and Pharmacokinetics of Long-acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442) are Consistent after Repeat Dosing: Results from the PROVENT Substudy

2025 · Andrew Ustianowski, Myron J Levin, et al. · Open Forum Infectious Diseases · 2

Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve

2026 · Huixia Zhang, Weifeng Tang, et al. · Clinical Pharmacokinetics

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial

2026 · Adora Rooyakkers, Lingyun Ye, et al. · Vaccine

Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study

2026 · Andrew Ustianowski, Myron J. Levin, et al. · Clinical Drug Investigation

Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID-19: a randomized, double-blind, placebo-controlled trial

2024 · Sergey N. Avdeev, Galina L. Ignatova, et al. · medRxiv

Clonal structure and epitope specificity of Ad5-nCoV vaccine-induced T cell response to SARS-CoV-2

2022 · Savely Sheetikov, Alexandra A Khmelevskaya, et al. · The Journal of Immunology

Works count: 9

Citation count: 252

H-index: 3

I10-index: 1